Copyright: ©Author(s) 2026.
World J Gastrointest Oncol. Nov 15, 2026; 18(11): 125273
Published online Nov 15, 2026. doi: 10.4251/wjgo.125273
Published online Nov 15, 2026. doi: 10.4251/wjgo.125273
Table 2 A summary of tissue-based biomarkers identified in ulcerative colitis-colorectal cancer and their clinical relevance for screening
| Biomarker | Clinical relevance | Advantages/limitations | Ref. |
| TP53 | 71% in low-grade dysplasia, 83% in high-grade dysplasia, 100% in adenocarcinoma; absent in uninvolved mucosa | Adjunctive biomarker to identify high-risk patients before histologic changes occur, predicting risk of evolution toward malignancy | [88,138-140] |
| p14ARF hypermethylation | 100% in dysplastic tissue vs 26% in non-dysplastic biopsies | Predictor of future dysplasia during surveillance | [141,142] |
| 1-8U gene (interferon-inducible) (IFITM3) | High expression in cancer and severely inflamed and cancerous UC mucosa; absent in normal tissue | Discrimination of high-risk areas before visible dysplasia | [143,144] |
| Telomere shortening + clonal expansions | 100% sensitivity, 80% specificity distinguishing progressors from non-progressors (early-onset UC) | Risk stratification in young patients with extensive disease | [145,146] |
| Associated with proximity to dysplasia | |||
| Aneuploidy (flow cytometry ploidy) | 5/6 patients with aneuploidy developed dysplasia in 1-2.5 years vs 0/19 without aneuploidy | Not routinely implemented by insufficient prospective validation, and the growing emphasis on gene-specific genomic alterations | [88,146-148] |
| Adjunctive marker in biopsies indefinite for dysplasia | |||
| Copy number variants (lpWGS-derived CNA score) | Cumulative chromosomal alterations before advanced neoplasia | Scalable, cost-effective tool to predict progression from low-grade dysplasia | [88,149,150] |
| Lack of prospective multicenter validation, standardized analytical pipelines and cut-off values, and generalizability beyond low-grade dysplasia cohorts | |||
| miR-9 methylation | Increases with age, disease duration, proximity to cancer | High-accuracy discrimination in rectal mucosa Lack of independent prospective validation and evidence supporting its use only within multi-marker methylation panels | [88,151,152] |
| Methylation panel (SFRP2, SFRP4, WIF1, APC1A, APC2) | Detects pre-cancerous and invasive neoplasia | Validated multiplex panel from a multicenter study (ENDCAP-C) Limited by the need for colonic biopsy, only moderate prediction of neoplastic progression in non-neoplastic mucosa, and the transition toward genome-wide biomarkers (e.g., CNA profiling and lpWGS) | [153,154] |
| Stool microbiome (16 rRNA sequencing) | Mucosal microbiota (Firmicutes/Bacteroidetes ratio) exhibit persistent dysbiosis UC-CRC | Positive association between Fermicutes and Proteobacteria Bacteroidetes and inflammatory markers with incidence of CRC | [155,156] |
| TP53-nuclear (IHC) + cytokeratin 7 | TP53 strong nuclear overexpression correlates with neoplastic progression | Useful adjunct when histology is ambiguous (indefinite for dysplasia) | [157-159] |
| CK7 not expressed in normal colonic mucosa. Expressed in all cases of epithelial dysplasia, with no difference between moderate and severe dysplasia | |||
| miR-21, miR126, miR146b-5p and miR-223 | Upregulation in active UC | Non-invasive disease monitoring | [160] |
| miR-142-3p, miR-144-3p, and miR-193a-5p | Overexpression in adenomas but down-regulated in CRC | Biomarker pre-cancer | [161] |
| miR-31, miR-135b and miR-106a | Tracking of malignant progression via expression profiling | Mucosal miRNAs that not only accurately discriminate dysplasia from normal mucosa but also indicate a higher risk of CRC and are expressed in UC-CRC | [162,163] |
| ctDNA, circulating tumor cells, exosomes, tumor-educated platelets | Reflect real-time molecular heterogeneity | Minimally invasive surveillance complementary to colonoscopy | [164] |
| Requires validation | |||
| KRAS mutations | Occur later, often co-occurring with TP53 Frequency of KRAS mutations increases continuously from non-dysplastic IBD colon to UC-CRC, and they are observed to be mutually exclusive with BRAF mutations | Limited clinical utility as a standalone biomarker | [165] |
| Invisible lesions in patients without IBD exhibit fewer KRAS and APC mutations compared with polypoid lesions, but show a higher frequency of BRAF mutations | KRAS mutations were enriched in non-dysplastic UC colon at approximately 14% | [166] |
- Citation: Delgado-Gonzalez P, Quiroz-Reyes AG, Simental-Mendía MA, Loaiza-Gutiérrez VL, Garza-Treviño EN. Inflammation-driven carcinogenesis in ulcerative colitis: Molecular and immunological pathways. World J Gastrointest Oncol 2026; 18(11): 125273
- URL: https://www.wjgnet.com/1948-5204/full/v18/i11/125273.htm
- DOI: https://dx.doi.org/10.4251/wjgo.125273